Representatives from universities around the country gathered to discuss how to reduce the burden of cancer at their institutions and in their communities.

Going for Gold is intended to reduce disparities in cancer diagnoses and deaths among minority populations in the United States.

Joya Delgado Harris, of the CEO Roundtable on Cancer, briefed the White House Cancer Moonshot on disparities in cancer care for vulnerable and historically disenfranchised communities at a meeting in Washington, D.C. on April 19.

Sharpless also served as acting commissioner of the U.S. Food and Drug Administration and director of UNC-Chapel Hill's Lineberger Cancer Center.

It is with profound sadness that the CEO Roundtable on Cancer announces the death of its founding chairman, Robert A. Ingram.

Directors of the CEO Roundtable on Cancer have elected David M. Reese, MD, Executive Vice President of Research and Development at Amgen, to a two-year term as Board Chairman effective immediately.

The CEO Roundtable on Cancer is recognizing two companies and three universities for their commitment to the health of employees, students and community members with CEO Cancer Gold Standard™ accreditation.

MD Anderson received the 2022 Charles A. Sanders Life Sciences Award at the CEO Roundtable’s Annual Meeting and Conference on Nov. 1. Merck and Dr. Granger each were honored with the Spirit of Health Award.

Three new companies have earned CEO Cancer Gold Standard accreditation from the CEO Roundtable on Cancer, recognizing their focus on building a healthier workplace by focusing on cancer risk reduction, early detection, access to clinical trials, and high-quality care.

Five new companies have joined the CEO Roundtable on Cancer and its campaign to do something more about cancer prevention, diagnosis, and treatment for their employees, their families, and their communities.

The CEO Roundtable on Cancer (CEORT) Board of Directors today announced that William C. Louv, PhD, will lead the organization as Chief Executive Officer effective immediately, and it has elected two new Directors: David M. Reese, MD, Executive Vice President of R&D at Amgen, and Major General Elder Granger, MD, President and CEO of THE 5Ps, LLC.

Charles A. Sanders Award presented to Amgen and CEO Robert A. Bradway and former Glaxo Wellcome CEO Robert A. Ingram;.Spirit of Health Award goes to B&C Associates Inc. Founder and CEO Robert J. Brown.

Collaboration with HBCUs, HSIs, Merck, Amgen and SAS Elevates Cancer Prevention, Diagnosis, Quality Treatment Addressing Disparities in Health

A paper outlining consensus disease definitions for neurological toxicities in cancer patients undergoing immune checkpoint inhibitor treatment was published this week in the Journal for ImmunoTherapy of Cancer (JITC) by a team of physicians at 16 institutions. Neurologists and oncologists at Massachusetts General Hospital with support from scientists at Project Data Sphere® led the team to deliver the first consensus-based definitions of disease and severity criteria for any immune-related toxicity. 

The CEO Roundtable on Cancer has elected Scott White, Company Group Chairman for North America at the Janssen Pharmaceutical Companies of Johnson & Johnson, to its Board of Directors.

The CEO Roundtable on Cancer has accredited BeiGene, Ltd., a global biotechnology company with the CEO Cancer Gold StandardTM recognizing its efforts to reduce the risk of cancer for its employees and covered family members.

Project Data Sphere’s open access data platform has achieved a major milestone: Boosting the impact of oncology research by contributing to publication of more than 100 peer-reviewed articles that impact research and clinical practice.

CARY, NC (March 25, 2021) -- The CEO Roundtable on Cancer has elected to its Board of Directors Dr. Belén Garijo, Vice Chair of the Executive Board and Deputy CEO of Merck KGaA, Darmstadt, Germany, and Dr. Peter WT Pisters, president of The University of Texas MD Anderson Cancer Center.